Gilead, Arcus scrap late-stage trial of cancer drug combo
12/12/2025 13:30
Dec 12 (Reuters) - Gilead Sciences GILD.O and Arcus Biosciences RCUS.N said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to show a survival benefit. (Reporting by Kamal Choudhury in Bengaluru; Editing by Anil D'Silva) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering